Such stratification based on HYAL1 expression in concordance with ERα status in breast cancer subtypes is suggested with our results showing significant lower expression of HYAL1 in breast tumors highly expressing ESR1, such as luminal A and luminal B subtypes. This evidence concerns the gene ERAL1 and breast neoplasm.